AT‐1001: a high‐affinity α3β4 nAChR ligand with novel nicotine‐suppressive pharmacology

The α3β4 subtype of nicotinic acetylcholine receptors (nAChRs) has been implicated in mediating nicotine reinforcement processes. AT‐1001 has been recently described as a high‐affinity and selective α3β4 nAChR antagonist that blocks nicotine self‐administration in rats. The aim of this study was to investigate the mechanism of action underlying the nicotine‐suppressive effects of AT‐1001.

[1]  N. Gilpin,et al.  Nicotine vapor inhalation escalates nicotine self‐administration , 2014, Addiction biology.

[2]  N. Zaveri,et al.  [125I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors , 2014, Neuropharmacology.

[3]  Gladys N. Pachas,et al.  Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. , 2014, JAMA.

[4]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Ligand-Gated Ion Channels , 2013, British journal of pharmacology.

[5]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[6]  R. Ciccocioppo,et al.  Pregabalin reduces cocaine self‐administration and relapse to cocaine seeking in the rat , 2013, Addiction biology.

[7]  W. Verhoeven,et al.  Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports , 2013, Journal of clinical psychopharmacology.

[8]  N. Zaveri,et al.  Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activity. , 2013, European journal of pharmacology.

[9]  S. Goldberg,et al.  Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. , 2012, The international journal of neuropsychopharmacology.

[10]  Adam Malik,et al.  Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™ , 2012, Clinical and experimental pharmacology & physiology.

[11]  M. Heilig,et al.  Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats , 2012, Pharmacology Biochemistry and Behavior.

[12]  A. Makriyannis,et al.  Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking , 2012, PloS one.

[13]  W. Zhou,et al.  AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats , 2012, Neuropsychopharmacology.

[14]  U. Maskos,et al.  Aversion to Nicotine Is Regulated by the Balanced Activity of β4 and α5 Nicotinic Receptor Subunits in the Medial Habenula , 2011, Neuron.

[15]  R. Hurst,et al.  Partial Agonists of the α3β4* Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats , 2011, Neuropsychopharmacology.

[16]  G. Koob,et al.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration , 2011, Psychopharmacology.

[17]  C. D. Fowler,et al.  Habenular α5* nicotinic receptor signaling controls nicotine intake , 2011, Nature.

[18]  Afshin Ghavami,et al.  The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  C. Kilkenny,et al.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines , 2010, British journal of pharmacology.

[20]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[21]  V. Tedesco,et al.  Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area α6β2* Receptors in Mediating Systemic Nicotine Effects on Dopamine Release, Locomotion, and Reinforcement , 2010, The Journal of Neuroscience.

[22]  S. Goldberg,et al.  Noradrenergic α1 Receptors as a Novel Target for the Treatment of Nicotine Addiction , 2010, Neuropsychopharmacology.

[23]  A. Lê,et al.  Coadministration of intravenous nicotine and oral alcohol in rats , 2010, Psychopharmacology.

[24]  E. O'Connor,et al.  The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats , 2010, Psychopharmacology.

[25]  J. Changeux,et al.  Crucial Role of α4 and α6 Nicotinic Acetylcholine Receptor Subunits from Ventral Tegmental Area in Systemic Nicotine Self-Administration , 2008, The Journal of Neuroscience.

[26]  L. Galanti.  Tobacco smoking cessation management: integrating varenicline in current practice , 2008, Vascular health and risk management.

[27]  S. Bartlett,et al.  Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking , 2007, Proceedings of the National Academy of Sciences.

[28]  J. Pezzullo,et al.  Chronic Nicotine Differentially Regulates α6- and β3-Containing Nicotinic Cholinergic Receptors in Rat Brain , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  R. J. Mather,et al.  Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.

[30]  F. Ivy Carroll,et al.  Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors , 2006, Molecular Pharmacology.

[31]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[32]  M. Picciotto.  Faculty Opinions recommendation of Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. , 2004 .

[33]  A. C. Collins,et al.  Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization , 2004, Science.

[34]  S. D. Glick,et al.  Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment , 2003, Pharmacology Biochemistry and Behavior.

[35]  J. Daly,et al.  Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  John L. Musachio,et al.  Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography , 2002 .

[37]  A. C. Collins,et al.  Characterization of [125I]epibatidine binding and nicotinic agonist‐mediated 86Rb+ efflux in interpeduncular nucleus and inferior colliculus of β2 null mutant mice , 2002 .

[38]  S. D. Glick,et al.  Development of Novel Medications for Drug Addiction: The Legacy of an African Shrub , 2000, Annals of the New York Academy of Sciences.

[39]  J. Changeux,et al.  Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice , 1999, Psychopharmacology.

[40]  G. Koob,et al.  Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats , 1999, Pharmacology Biochemistry and Behavior.

[41]  J. Changeux,et al.  Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine , 1998, Nature.

[42]  N. R. Richardson,et al.  Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy , 1996, Journal of Neuroscience Methods.

[43]  T. Kenakin.  The quantification of relative efficacy of agonists. , 1985, Journal of pharmacological methods.

[44]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[45]  P. Baldwin,et al.  The Role of the Habenula in Nicotine Addiction. , 2011, Journal of addiction research & therapy.

[46]  Qun Lu,et al.  Habenular a5 nicotinic receptor subunit signalling controls nicotine intake , 2011 .

[47]  R. Hurst,et al.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. , 2007, Neuropharmacology.

[48]  S. Bartlett,et al.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Pezzullo,et al.  Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. , 2007, The Journal of pharmacology and experimental therapeutics.

[50]  F. Carroll,et al.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. , 2006, Molecular pharmacology.

[51]  N. Rigotti,et al.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. , 2006, JAMA.

[52]  A. C. Collins,et al.  Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice. , 2002, Journal of Neurochemistry.

[53]  K. Kellar,et al.  Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. , 2002, Journal of neurochemistry.